Conditionally replicating adenovirus SG500-expressed mutant Dm-dNK gene for breast cancer therapy

  • Authors:
    • Wenzhi Qu
    • Zhi Zhu
    • Lei Zhao
    • Anning He
    • Xinyu Zheng
  • View Affiliations

  • Published online on: October 11, 2012     https://doi.org/10.3892/ijo.2012.1657
  • Pages: 2175-2183
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of this analysis was to investigate the enzyme activity and specificity of using adenovirus-mediated Drosophila melanogaster deoxyribonucleoside kinase (Dm-dNK) mutants in combination with gemcitabine. Compared with herpes simplex type 1 thymidine kinase (HSV-TK) and other known dNKs, this Dm-dNK enzyme has a broader substrate specificity and a higher catalytic rate. We created the Dm-dNK mutants (dNKmu) by site-directed mutagenesis at the sites of 244E, 245S, 251S and 252R, with the last 10 amino acids in the amino acid sequence randomly mutated. We evaluated the enzyme activity and substrate specificity. The engineered enzymes showed a relative increase in phosphorylation in the nucleoside analogs of BVDU ((E)-5‑(2-Bromovinyl)-2'-deoxyuridine) or gemcitabine (DFDC, 2',2'-difluoro-deoxycytidine) compared with the wild-type enzyme. The dNKmu enzymes were expressed in the breast cancer cell lines MDA-MB-231 (ER-) and MCF7 (ER+). In studying the sensitivity of the cell lines to DFDC, conditionally replicative adenovirus (CRAd) SG500-dNKmu showed higher expression and enzymatic activity than the replication-defective adenovirus SG500 in cancer cells, but with less cytotoxicity to cancer cells than that of SG500. Our data suggest that the triple phosphorylated DFDC catalyzed by dNKmu inhibited the replication of adenovirus with a simultaneous positive therapeutic effect to cancer cells. Therefore, concomitant use of the SG500‑dNKmu and DFDC could be a novel targeted strategy in suicide gene therapy with safe control of excessive virus replication.
View Figures
View References

Related Articles

Journal Cover

December 2012
Volume 41 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Qu W, Zhu Z, Zhao L, He A and Zheng X: Conditionally replicating adenovirus SG500-expressed mutant Dm-dNK gene for breast cancer therapy. Int J Oncol 41: 2175-2183, 2012
APA
Qu, W., Zhu, Z., Zhao, L., He, A., & Zheng, X. (2012). Conditionally replicating adenovirus SG500-expressed mutant Dm-dNK gene for breast cancer therapy. International Journal of Oncology, 41, 2175-2183. https://doi.org/10.3892/ijo.2012.1657
MLA
Qu, W., Zhu, Z., Zhao, L., He, A., Zheng, X."Conditionally replicating adenovirus SG500-expressed mutant Dm-dNK gene for breast cancer therapy". International Journal of Oncology 41.6 (2012): 2175-2183.
Chicago
Qu, W., Zhu, Z., Zhao, L., He, A., Zheng, X."Conditionally replicating adenovirus SG500-expressed mutant Dm-dNK gene for breast cancer therapy". International Journal of Oncology 41, no. 6 (2012): 2175-2183. https://doi.org/10.3892/ijo.2012.1657